Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerLuis Paz‐Ares, Dariusz M. Kowalski, Alexander Luft et al.|New England Journal of Medicine|2018Cited by 3.7k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%Martin Reck, Julie R. Brahmer, Ali Tafreshi et al.|Journal of Clinical Oncology|2021Cited by 1.1k
Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).Luis Paz‐Ares, Dariusz M. Kowalski, Alexander Luft et al.|Journal of Clinical Oncology|2018Cited by 121
A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.Giorgio V. Scagliotti, Ramaswamy Govindan, Igor Bondarenko et al.|Journal of Clinical Oncology|2018Cited by 10